A Study Describing the Efficacy and Safety of Belimumab Administered in Adult Participants With Early Systemic Lupus Erythematosus (SLE)
NCT ID: NCT06411249
Last Updated: 2025-11-26
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE4
350 participants
INTERVENTIONAL
2024-06-06
2029-05-29
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study of Belimumab in Subjects With Systemic Lupus Erythematosus
NCT00410384
A Study of Belimumab Administered Subcutaneously in Subjects With Systemic Lupus Erythematosus (SLE)
NCT01484496
Phase 2 Study of Belimumab Administered Subcutaneously to Subjects With Systemic Lupus Erythematosus (SLE)
NCT00732940
A Phase 2B Open-Label, Single-Arm, Repeat-Dose Study to Evaluate the Reliability of an Autoinjector
NCT02124798
A Study to Evaluate the Effect of Belimumab on Vaccine Responses in Subjects With Systemic Lupus Erythematosus (SLE)
NCT01597492
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Belimumab (GSK1550188)
Participants will receive GSK1550188.
Belimumab (GSK1550188)
GSK1550188 will be administered subcutaneously.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Belimumab (GSK1550188)
GSK1550188 will be administered subcutaneously.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Have unequivocally positive autoantibody test results defined as an Anti-nuclear antibody (ANA) titer greater than or equal to (≥) 1:80 and/or a positive anti-Double stranded deoxyribonucleic acid (dsDNA) serum antibody test from 2 independent time points
* Active SLE defined as:
* Clinical SLEDAI-2K (excluding anti-dsDNA and C3/C4) score greater than (\>) 4, OR
* Clinical SLEDAI-2K (excluding anti-dsDNA and C3/C4) less than or equal to (≤) 4 and prednisone or equivalent dose ≥10 milligram per day (mg/day)
* The Systematic Lupus International Collaborating Clinics/American College of Rheumatology (SLICC/ACR) Damage Index (SDI) = 0 at Screening
* Male and/or female; a female participant is eligible to participate if she is not pregnant, not breastfeeding, and at least one of the following conditions applies:
* Not a Woman of childbearing potential (WOCBP) OR
* Is a WOCBP and using a contraceptive method that is highly effective
* Capable of giving signed informed consent
Exclusion Criteria
* Have clinical evidence of significant unstable or uncontrolled acute or chronic diseases not due to SLE (i.e., cardiovascular, pulmonary, hematologic, gastrointestinal (GI), hepatic, renal, neurological, psychiatric, malignancy, or infectious diseases) and/or a planned surgical procedure, which, in the opinion of the principal investigator (PI), could confound the results of the clinical study or put the participant at undue risk.
* Participants with history of major organ transplant or hematopoietic stem cell/marrow transplant or renal transplant.
* Have an acute or chronic infection including requiring management as follows:
* Currently on any suppressive therapy for a chronic infection such as pneumocystis, cytomegalovirus, herpes simplex virus, herpes zoster, or atypical mycobacteria.
* A serious infection requiring treatment with intravenous or Intramuscular (IV/IM) antibiotics and/or hospitalization if the last dose of antibiotics or the hospital discharge date was within 60 days of the first day of dosing (Day 1). Prophylactic anti-infective treatment is allowed.
* Confirmed active or untreated latent tuberculosis (TB):
* Diagnosis of active TB confirmed by: 1) evidence of active TB disease from chest imaging (posterior anterior and lateral x-rays or chest computed tomography \[CT\]), 2) medical history and physical examination, and 3) either positive microscopy smear/culture for mycobacteria or positive TB polymerase chain reaction (PCR), i.e., Xpert. A tuberculin skin test (TST) or an interferon gamma release assay (IGRA) will be done for all participants. A positive TST or a positive (not indeterminate) IGRA TB test such as QuantiFERON-TB Gold Plus test is indicative but not required for diagnosis of active TB. A positive TST is defined as a skin induration ≥5 millimeter (mm) at 48 to 72 hours (regardless of Bacillus Calmette-Guerin or other vaccination history).
* Untreated latent tuberculosis infection (LTBI) confirmed by: 1) no evidence of active TB based on chest imaging, medical history and physical examination and laboratory evaluation of sputum; and 2) a positive TST, defined as a skin induration \>5 mm at 48 to 72 hours, regardless of Bacillus Calmette-Guerin or other vaccination history); or a positive (not indeterminate) IGRA TB test such as QuantiFERON-TB Gold Plus test. Those with IGRA positive tests or positive TST who can document ongoing LTBI treatment for at least 4 weeks may be enrolled. Those with IGRA positive tests with documentation of the following may also be enrolled:
* Successful completion of treatment for active TB.
* Completion of treatment for LTBI (with treatment as per local practice, for example: 3 months of isoniazid and rifampin or 4 months of rifampin or 3 months weekly isoniazid and rifapentine, or 9 months of isoniazid).
* Confirmed Progressive multifocal leukoencephalopathy (PML) or unexplained new-onset or deteriorating neurologic signs and symptoms.
* Have severe active central nervous system (CNS) lupus (including seizures, psychosis, organic brain syndrome, Cerebrovascular accident (CVA), cerebritis, or CNS vasculitis) requiring therapeutic intervention within 60 days of Screening.
* Active Lupus Nephritis defined as active urinary sediment and/or proteinuria \>500 milligrams (mg) per 24 hours, or equivalent using spot urine protein to creatinine ratio, requiring induction therapy not permitted by protocol.
* Participants with patient health questionnaire (PHQ)-9 score ≥10 that in the opinion of a mental healthcare professional pose a serious suicide risk, or any history of suicidal behavior in the last 6 months and/or any suicidal ideation in the last 2 months, or who in the investigator's judgment, poses a significant suicide risk. NOTE: For participants with a PHQ-9 score ≥10, at the Screening visit or at the day 1 visit before the first administration of the study drug, it is required that they be referred for an assessment by a mental healthcare professional (e.g., locally licensed psychiatrist, psychologist, or master's level therapist) before the investigator makes a final decision regarding suitability for enrollment.
* Known to have titers of human anti-mouse antibody or history of hypersensitivity reactions when treated with diagnostic or therapeutic monoclonal antibodies
* Live or live-attenuated vaccine(s) within 35 days prior to Screening or plans to receive such vaccines during the Screening period or during the clinical study
* Chronic oral steroid use for a non-SLE disorder at the Screening study visit (e.g., for asthma). Inhaled steroid use will be allowed.
* Treatment at or prior to Screening study visit:
* Treatment at Screening study visit with any of the following:
* Azathioprine (AZA) \>200 mg/day
* Methotrexate (MTX) (any formulation) \>25 mg/week
* Mycophenolate mofetil (MMF) (oral \[PO\])/MMF hydrochloride (IV) \>2 grams (g)/day
* Mycophenolate acid/sodium (PO) \>1.44 g/day
* Oral cyclophosphamide \>2.5 mg/kilograms (kg)/day
* Tacrolimus \>0.2 mg/kg/day
* Cyclosporine (PO) \>2.5 mg/kg/day
* Treatment within specified timeframe prior to Screening:
* Intra-articular, IM, or IV corticosteroids within 6 weeks of Day 1
* Daily use of \>1 Nonsteroidal anti-inflammatory (NSAID) within 2 weeks prior to Day 1
* Treatment at any time prior to Screening with any of the following:
* Second line use of conventional immunosuppressants (ISs) or anti-malarials (AMs)
* Commercially available Belimumab (BEL)
* Anifrolumab
* Rituximab or other B cell depleting therapies
* Anti-tumor necrosis factor (TNF) therapy (e.g., adalimumab, etanercept, infliximab)
* Other treatments with effects on the immune system (e.g., abatacept, interleukin-1 receptor antagonist \[anakinra\], Janus kinase (JAK) inhibitors)
* IV cyclophosphamide
* IV immunoglobulin
* Plasmapheresis
* History of primary immunodeficiency, or hypogammaglobulinemia (Immunoglobulin G \[IgG\] \<400 mg/deciliter \[dL\]) or Immunoglobulin A (IgA) deficiency (IgA \<10 mg/dL) at Screening
* Have a Grade 3 or greater neutropenia, defined as absolute neutrophil count \<1000/cubic millimeter (mm3) (\<1.0 x109/liter \[L\]) based on the Common terminology criteria for adverse events (CTCAE) version (v) 5.0
* Alanine aminotransferase \>2 x upper limit of normal (ULN)
* Total bilirubin \>1.5 x ULN (isolated bilirubin \>1.5 x ULN is acceptable if bilirubin is fractionated and direct bilirubin \<35 percent \[%\]). Participants with Gilbert's syndrome can be included with total bilirubin \>1.5xULN as long as direct bilirubin is ≤1.5xULN. Cirrhosis or current unstable liver or biliary disease per investigator assessment defined by the presence of ascites, encephalopathy, coagulopathy, hypoalbuminemia, esophageal or gastric varices, persistent jaundice. NOTE: Stable non-cirrhotic chronic liver disease (including Gilbert's syndrome), asymptomatic gallstones, and chronic stable hepatitis B (in whom Hepatitis D \[HDV\] has been excluded) or C are acceptable if participant otherwise meets entry criteria.
* Have any other clinically significant abnormal laboratory value, that in the opinion of the investigator, is capable of significantly altering the absorption, metabolism, or elimination of the clinical study intervention; or constitutes a risk when taking the clinical study intervention or interferes with the interpretation of the clinical study data.
* Positive Human immunodeficiency virus (HIV) antibody test
* Serologic evidence of Hepatitis B (HB) infection based on the results of testing for hepatitis B surface antigen (HBsAg), anti-hepatitis B core (HBc) and anti-HBs will be excluded as follows:
* Participants positive for HBsAg.
* Participants negative for HBsAg but positive for Anti-HBc and detectable hepatitis B virus (HBV) DNA, regardless of Anti-HBs antibody status.
* Positive Hepatitis C antibody test result at Screening or within 3 months prior to starting study intervention. NOTE: Participants with positive Hepatitis C antibody due to prior resolved disease can be enrolled, only if a confirmatory negative Hepatitis C Ribonucleic acid (RNA) test is obtained.
* Positive Hepatitis C RNA test result at Screening or within 3 months prior to first dose of study intervention. NOTE: Test is optional and participants with negative Hepatitis C antibody test are not required to also undergo Hepatitis C RNA testing.
* Sensitivity to the clinical study intervention, or components thereof, or monoclonal antibodies or drug or other allergy that, in the opinion of the investigator, contraindicates participation in the clinical study
* Current drug or alcohol dependence, or a history of drug or alcohol abuse or dependence within 364 days prior to Day 1
* Current enrolment or past participation in any other clinical study involving an investigational study intervention (including investigational vaccines) within 3 months or 5 half-lives of the investigational drug (whichever is longer) before enrolment
* Unable to administer clinical study intervention by subcutaneous (SC) auto-injector at home and has no other reliable resource to administer the study intervention at home.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
GlaxoSmithKline
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
GSK Clinical Trials
Role: STUDY_DIRECTOR
GlaxoSmithKline
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
GSK Investigational Site
Anniston, Alabama, United States
GSK Investigational Site
Flagstaff, Arizona, United States
GSK Investigational Site
Mesa, Arizona, United States
GSK Investigational Site
Tucson, Arizona, United States
GSK Investigational Site
Covina, California, United States
GSK Investigational Site
Fontana, California, United States
GSK Investigational Site
Fullerton, California, United States
GSK Investigational Site
Long Beach, California, United States
GSK Investigational Site
Los Angeles, California, United States
GSK Investigational Site
Mission Hills, California, United States
GSK Investigational Site
San Diego, California, United States
GSK Investigational Site
Temecula, California, United States
GSK Investigational Site
Tujunga, California, United States
GSK Investigational Site
Van Nuys, California, United States
GSK Investigational Site
Van Nuys, California, United States
GSK Investigational Site
Whittier, California, United States
GSK Investigational Site
Aventura, Florida, United States
GSK Investigational Site
Clearwater, Florida, United States
GSK Investigational Site
Miami, Florida, United States
GSK Investigational Site
Tamarac, Florida, United States
GSK Investigational Site
Tampa, Florida, United States
GSK Investigational Site
Atlanta, Georgia, United States
GSK Investigational Site
Sugar Hill, Georgia, United States
GSK Investigational Site
Morton Grove, Illinois, United States
GSK Investigational Site
Rockford, Illinois, United States
GSK Investigational Site
Baton Rouge, Louisiana, United States
GSK Investigational Site
New Orleans, Louisiana, United States
GSK Investigational Site
Shreveport, Louisiana, United States
GSK Investigational Site
Detroit, Michigan, United States
GSK Investigational Site
Lansing, Michigan, United States
GSK Investigational Site
Sparta, New Jersey, United States
GSK Investigational Site
Brooklyn, New York, United States
GSK Investigational Site
Charlotte, North Carolina, United States
GSK Investigational Site
Winston-Salem, North Carolina, United States
GSK Investigational Site
Duncansville, Pennsylvania, United States
GSK Investigational Site
Philadelphia, Pennsylvania, United States
GSK Investigational Site
Austin, Texas, United States
GSK Investigational Site
Baytown, Texas, United States
GSK Investigational Site
Colleyville, Texas, United States
GSK Investigational Site
Fort Worth, Texas, United States
GSK Investigational Site
Houston, Texas, United States
GSK Investigational Site
Katy, Texas, United States
GSK Investigational Site
Plano, Texas, United States
GSK Investigational Site
Waco, Texas, United States
GSK Investigational Site
Danville, Virginia, United States
GSK Investigational Site
Glendale, Wisconsin, United States
GSK Investigational Site
Berazategui, , Argentina
GSK Investigational Site
Buenos Aires, , Argentina
GSK Investigational Site
Buenos Aires, , Argentina
GSK Investigational Site
Ciudad Autonoma Buenos Aires, , Argentina
GSK Investigational Site
Ciudad Autonoma de Buenos Aire, , Argentina
GSK Investigational Site
La Plata, , Argentina
GSK Investigational Site
Mar del Plata, , Argentina
GSK Investigational Site
Quilmes, , Argentina
GSK Investigational Site
San Miguel de Tucumán, , Argentina
GSK Investigational Site
Santa Fe, , Argentina
GSK Investigational Site
Belo Horizonte, , Brazil
GSK Investigational Site
Cuiabá, , Brazil
GSK Investigational Site
Juiz de Fora, , Brazil
GSK Investigational Site
Passo Fundo, , Brazil
GSK Investigational Site
Porto Alegre, , Brazil
GSK Investigational Site
Porto Alegre, , Brazil
GSK Investigational Site
Porto Alegre, , Brazil
GSK Investigational Site
Salvador, , Brazil
GSK Investigational Site
São José do Rio Preto, , Brazil
GSK Investigational Site
São Paulo, , Brazil
GSK Investigational Site
São Paulo, , Brazil
GSK Investigational Site
Angers, , France
GSK Investigational Site
Lille, , France
GSK Investigational Site
Pessac, , France
GSK Investigational Site
Rennes, , France
GSK Investigational Site
Saint-Priest-en-Jarez, , France
GSK Investigational Site
Toulouse, , France
GSK Investigational Site
Herne, , Germany
GSK Investigational Site
Lübeck, , Germany
GSK Investigational Site
Mainz, , Germany
GSK Investigational Site
Mainz, , Germany
GSK Investigational Site
Meerbusch, , Germany
GSK Investigational Site
Athens, , Greece
GSK Investigational Site
Athens, , Greece
GSK Investigational Site
Athens, , Greece
GSK Investigational Site
Heraklion, , Greece
GSK Investigational Site
Thessaloniki, , Greece
GSK Investigational Site
Brescia, , Italy
GSK Investigational Site
Ferrara, , Italy
GSK Investigational Site
Milan, , Italy
GSK Investigational Site
Pisa, , Italy
GSK Investigational Site
Reggio Emilia, , Italy
GSK Investigational Site
Rome, , Italy
GSK Investigational Site
Rozzano, , Italy
GSK Investigational Site
Fukuoka, , Japan
GSK Investigational Site
Kanagawa, , Japan
GSK Investigational Site
Miyagi, , Japan
GSK Investigational Site
Osaka, , Japan
GSK Investigational Site
Tokyo, , Japan
GSK Investigational Site
Cuauhtémoc, Mexico City, Mexico
GSK Investigational Site
DF, , Mexico
GSK Investigational Site
Guadalajara Jalisco, , Mexico
GSK Investigational Site
León, , Mexico
GSK Investigational Site
Mexico City, , Mexico
GSK Investigational Site
Mexico City, , Mexico
GSK Investigational Site
Mérida, , Mexico
GSK Investigational Site
Monterrey Nuevo LeOn, , Mexico
GSK Investigational Site
San Luis Potosí City, , Mexico
GSK Investigational Site
Torreón, , Mexico
GSK Investigational Site
Almada, , Portugal
GSK Investigational Site
Barcelona, , Spain
GSK Investigational Site
Córdoba, , Spain
GSK Investigational Site
Murcia, , Spain
GSK Investigational Site
Seville, , Spain
GSK Investigational Site
Valladolid, , Spain
GSK Investigational Site
VigoPontevedra, , Spain
GSK Investigational Site
Villajoyosa, , Spain
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2023-509146-35-00
Identifier Type: REGISTRY
Identifier Source: secondary_id
219240
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.